Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2001

View Archived Issues

Licensing opportunity from NIH: virus-like particles as unlinked adjuvants

Karo Bio updates collaborative and internal development projects

Micrologix suspends MBI-853NL development program; focus shifts to later stage products

Enrollment complete in second pivotal phase III trial of Cidecin

RANTES analogue stimulates HIV replication at high concentrations via the MAPK/ERK pathway

Overall superior safety profile of BMS-232632 vs. older protease inhibitors confirmed

Resistance profile of BCH-10618 suggests further development warranted

Long-term results reported from Thai study of Remune monotherapy

Small-molecule CCR5 antagonists as a promising new class of antiretrovirals

Autoimmune and inflammatory disease therapy alliance between Icos and Biogen

Genome Therapeutics and Wyeth-Ayerst extend osteoporosis genomics alliance

Agreement signed for codevelopment of tissue-remodeling COPD treatment

Controlled trial shows no additional benefit for montelukast in difficult-to-treat asthma patients

Transdermal dopamine agonist reduces levodopa use in PD

Immunex seeks FDA approval of Enbrel for psoriatic arthritis

Thyroid disease therapy now available in Japan

GeneTrove division of Isis teams up with Celera Genomics for antisense gene functionalization

Antiinflammatory and cardioprotective effects of simvastatin in ApoE-deficient mice

EluSys raises funds to support Heteropolymer development program

Neurochem provides update on Fibrillex development

Vion's Triapine enters second phase I combination trial

Aventis gains license to Asta Medica's dexlipotam

Selective ERbeta receptor agonists claimed for use in osteoporosis

Naturally produced compound WK-6326 inhibits IL-4 activity and bacterial growth

New compounds from Alcon particularly useful for treatment of dry eye

Melatonin receptor ligands exert potent effects on circadian rhythms

Neuroprotective aminoalcohol derivatives designed by Seikagaku

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...